Your browser doesn't support javascript.
loading
Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
Yamasaki, S; Suzuki, R; Hatano, K; Fukushima, K; Iida, H; Morishima, S; Suehiro, Y; Fukuda, T; Uchida, N; Uchiyama, H; Ikeda, H; Yokota, A; Tsukasaki, K; Yamaguchi, H; Kuroda, J; Nakamae, H; Adachi, Y; Matsuoka, K-I; Nakamura, Y; Atsuta, Y; Suzumiya, J.
Afiliación
  • Yamasaki S; Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
  • Suzuki R; Department of Oncology and Haematology, Shimane University Hospital, Izumo, Japan.
  • Hatano K; Division of Hematology and Cell Therapy, Jichi Medical University, Shimotsuke, Japan.
  • Fukushima K; Division of Hematology, Rinku General Medical Center, Izumisano, Japan.
  • Iida H; Division of Cell Therapy, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Morishima S; Department of Hematology and Oncology, Fujita Health University School of Medicine, Toyoake, Japan.
  • Suehiro Y; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Fukuda T; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Uchida N; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
  • Uchiyama H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
  • Ikeda H; Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University Hospital, Sapporo, Japan.
  • Yokota A; Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
  • Tsukasaki K; Hematology Division, National Cancer Center Hospital East, Kashiwa, Japan.
  • Yamaguchi H; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Nakamae H; Department of Hematology, Osaka City University Hospital, Osaka, Japan.
  • Adachi Y; Department of Internal Medicine, Japan Community Health Care Organization Kobe Central Hospital, Kobe, Japan.
  • Matsuoka KI; Division of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Nakamura Y; Third Department of Internal of Medicine, Yamaguchi University School of Medicine, Ube, Japan.
  • Atsuta Y; Department of Healthcare Administration, Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
  • Suzumiya J; Department of Oncology and Haematology, Shimane University Hospital, Izumo, Japan.
Bone Marrow Transplant ; 52(7): 969-976, 2017 Jul.
Article en En | MEDLINE | ID: mdl-28368379
Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Neoplasias Primarias Secundarias / Trasplante de Células Madre Hematopoyéticas / Linfoma Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2017 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Neoplasias Primarias Secundarias / Trasplante de Células Madre Hematopoyéticas / Linfoma Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2017 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido